

OFFICIAL

AUG 20 2004

**FROMMER LAWRENCE & HAUG LLP**

745 Fifth Avenue  
New York, New York 10151  
Telephone: (212) 588-0800  
Facsimile: (212) 588-0500  
E-mail: Firm@flhlaw.com

**FACSIMILE COVER LETTER**

**To:** SPE Gary Kunz  
**Firm:** United States Patent and Trademark Office  
**Facsimile:** 703 872 9306  
**From:** Thomas J. Kowalski  
**Date:** August 20, 2004  
**Re:** USSN 10/084,235  
**Number of Pages:** 19  
(including cover page)

---

If you do not receive all pages or are unable to read the transmission, please call and ask for Angela (Ext. 2198).

---

---

**CONFIDENTIALITY NOTICE**

The documents accompanying this transmission contain confidential information intended for a specific individual and purpose. The information is private, and is legally protected by law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this facsimile is strictly prohibited.

00213248

**OFFICIAL** PATENT  
674519-2001.4  
USSN 10/084,235

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Michael John Reed et al.  
 Serial No. : 10/084,235  
 For : STEROID SULPHATASE INHIBITORS  
 Filed : February 25, 2002  
 Examiner : Badio, Barbara P.  
 Art Unit : 1616

**RECEIVED**  
**CENTRAL FAX CENTER**  
 AUG 20 2004

745 Fifth Avenue, New York, NY 10151

**FACSIMILE**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Angela M. Collison, Reg. No. 51,107

\_\_\_\_\_  
Type or print name of  
person signing certification

*Angela M. Collison*  
\_\_\_\_\_  
Signature

August 20, 2004  
\_\_\_\_\_  
Date of Signature

**SUPPLEMENTAL RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in further response to the November 14, 2003 Office Action and is supplemental to the Amendment filed May 14, 2004. It is believed that no fee is required by entry of this paper, however the Commissioner is hereby authorized to charge any required fee, and to credit any overpayment in fees, to Deposit Account 50-0320.

PATENT  
674519-2001.4  
USSN 10/084,235

Further to the August 4, 2004 telephone conversation between SPE Kunz and Thomas Kowalski, for which SPE Kunz is thanked for the many courtesies extended therein, Applicants requested that Chemical Abstracts Services review CAPLUS record 1984:524941/AN. As shown by the enclosed email transcript (Exhibit 1), we were informed on August 12, 2004 by Tom Tomaszewski of CAS Customer Care that the "Registry Number 91490-65-2D will be replaced with 57-63-6D".

The record for 57-63-6D is also contained in the email transcript, and the Examiner's attention is respectfully drawn to the fact that the erroneous chemical name, 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-sulfamate, (17alpha), has been removed from the record. Also enclosed as Exhibit 2 is the transcript from a STN search for the new record, which also includes the parent record, 57-63-6. As you can see, neither 57-63-6 or 57-63-6D contain the erroneous chemical name.

Applicants respectfully assert that in view of the foregoing, the remaining art rejections based on the erroneous record must be withdrawn. Specifically, claims 6-11, 17, 18 and 20 were rejected under 35 U.S.C. 103(a) allegedly as being unpatentable over The Registry Handbook (1984 Supplement) in view of Schwarz et al. (DD 114806 and Hirsch (US Patent No. 4,075,351).

Simply, as CAS Registry Number 91490-65-2D has been replaced with 57-63-6D, the very reference relied upon in the Office Action has been corrected; in other words, Registry number 91490-65-2D, no longer exists, and its replacement, 57-63-6D does not include the erroneous chemical name, 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-sulfamate, (17alpha). Applicants respectfully assert that a rejection based on a CAS registry number that has been removed cannot stand. Accordingly, reconsideration and withdrawal of the rejections of the claims under 35 U.S.C. §103, are respectfully requested.

#### **REQUEST FOR FURTHER INTERVIEW & CONCLUSION**

If any issue remains as an impediment to allowance, a further interview is respectfully requested, with the Examiner invited to contact the undersigned telephonically to arrange a mutually convenient time and manner therefore.

In view of the remarks and attachments herewith, and the matters previously discussed with SPE Kunz (for which SPE Kunz is again thanked for the courtesies extended therein), the

PATENT  
674519-2001.4  
USSN 10/084,235

application is in condition for allowance. Favorable reconsideration of the application, and prompt issuance of a Notice of Allowance are earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By: *Thomas J. Kowalski by Angela M. Collison*  
Thomas J. Kowalski  
Reg. No. 32,147  
Angela M. Collison  
Reg. No. 51,107  
(212) 588-0800